10-K: Kodiak Sciences 2025 Annual Report: Clinical Progress & Outlook

Kodiak Sciences reports significant clinical trial advancements for its retinal disease pipeline, including successful Phase 3 studies for Zenkuda, alongside substantial net losses and going concern doubt.

Summary

• Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company developing three late-stage clinical programs: tarcocimab tedromer (Zenkuda), KSI-501, and KSI-101, all based on its Antibody Biopolymer Conjugate (ABC) platform.
• Zenkuda, an anti-VEGF therapy, has completed four successful Phase 3 pivotal studies: GLOW1 and GLOW2 in diabetic retinopathy (DR), BEACON in retinal vein occlusion (RVO), and DAYLIGHT in wet age-related macular degeneration (wet AMD).
• In GLOW1 and GLOW2, Zenkuda achieved 41.1% and 62.5% of patients, respectively, demonstrating at least a 2-step improvement on the DRSS score versus sham (p-value < 0.0001 for both), with 100% of patients on extended 6-month dosing at Year 1 in DR.
• The BEACON study showed Zenkuda's matched efficacy with differentiated durability against aflibercept, with 47% of patients requiring no additional injections in the second 6 months after initial dosing, compared to 37% for aflibercept.
• The DAYLIGHT study demonstrated non-inferior efficacy and compelling safety for Zenkuda at a once-monthly dosing interval in treatment-naive wet AMD.
• The company plans to submit a Biologics License Application (BLA) for tarcocimab in DR, RVO, and wet AMD in 2026, potentially including data from the ongoing Phase 3 DAYBREAK study.
• KSI-501, an anti-IL-6, VEGF-trap bispecific therapy, is currently in the Phase 3 DAYBREAK study for wet AMD, with topline data expected in 3Q 2026.
• KSI-101, a high-strength bispecific protein targeting IL-6 and VEGF for macular edema secondary to inflammation (MESI), showed meaningful visual and anatomical gains in its Phase 1b APEX study, with Phase 3 PEAK and PINNACLE studies actively enrolling patients.
• Topline data for PEAK and PINNACLE are expected in 4Q 2026 and 2Q 2027, respectively.
• Kodiak reported a net loss of $229.9 million for the year ended December 31, 2025, an increase from $176.2 million in 2024, and an accumulated deficit of $1,559 million.
• Cash and cash equivalents stood at $209.9 million as of December 31, 2025.
• The company completed an equity offering in December 2025, issuing 8 million shares at $23.00 per share, generating net proceeds of $173.0 million.
• Substantial doubt exists regarding the company's ability to continue as a going concern, necessitating additional capital raises.
• Research and development expenses increased by $56.3 million (45%) to $182.4 million in 2025, primarily due to increased costs for the DAYBREAK, PEAK, and PINNACLE clinical trials and biopolymer manufacturing activities.
• General and administrative expenses decreased by $8.7 million (14%) to $52.0 million in 2025, mainly due to lower stock compensation expense and reduced net rent after subleasing a Palo Alto building.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While significant clinical progress and positive trial results for key product candidates are encouraging, the substantial net losses and explicit 'going concern' doubt present a material financial risk that overshadows the pipeline advancements.

Positives

• Zenkuda (tarcocimab) successfully met primary efficacy endpoints in four Phase 3 pivotal studies: GLOW1 and GLOW2 (diabetic retinopathy), BEACON (retinal vein occlusion), and DAYLIGHT (wet AMD).
• In GLOW1 and GLOW2, Zenkuda demonstrated strong efficacy in treating existing diabetic retinopathy and preventing sight-threatening complications, with 41.1% and 62.5% of patients achieving at least a 2-step DRSS improvement, respectively, and 100% on extended 6-month dosing at Year 1.
• The BEACON study highlighted Zenkuda's differentiated durability, with 47% of patients requiring no additional injections in the second six months while matching vision and anatomical outcomes of aflibercept-treated patients, who received materially more injections.
• KSI-101's Phase 1b APEX study showed meaningful visual and anatomical gains in both diabetic macular edema and macular edema secondary to inflammation (MESI), with a favorable safety profile.
• The company has commissioned and obtained regulatory approval for Ursus, a dedicated commercial-scale drug substance manufacturing facility built in collaboration with Lonza, positioning it for potential market share capture.
• Kodiak has retained all global rights to its product candidates, preserving future value and allowing agile decision-making.
• The company successfully completed an equity offering in December 2025, raising $173.0 million in net proceeds, which provides additional liquidity.

Negatives

• Kodiak Sciences has incurred significant net losses in each period since its inception, with a net loss of $229.9 million in 2025, an increase from $176.2 million in 2024.
• The company has an accumulated deficit of $1,559 million as of December 31, 2025.
• There is substantial doubt regarding the company's ability to continue as a going concern, indicating a need for additional financing.
• Zenkuda failed to meet primary efficacy endpoints in two prior Phase 3 studies, GLEAM and GLIMMER (diabetic macular edema), and the Phase 2b/3 DAZZLE study (wet AMD).
• An unexpected increase in cataract adverse events (19% with tarcocimab vs. 9% with aflibercept) was reported in the GLEAM and GLIMMER studies, which likely contributed to their failure.
• The company has no products approved for commercial sale and has never generated revenue from product sales.
• Interest income decreased by $6.6 million in 2025 compared to 2024, attributable to lower cash balances and reduced rates of return.

Risks

• The company is in the clinical stage of drug development with a limited operating history and no products approved for commercial sale, making future success and viability difficult to evaluate.
• Continued significant and increasing net losses are anticipated for the foreseeable future, and the company's financial condition raises substantial doubt about its ability to continue as a going concern.
• Failure to obtain additional financing may prevent the completion of development and commercialization of product candidates.
• Drug development is highly uncertain, and there is no guarantee that any product candidates will receive regulatory approval or generate revenue/profitability.
• The failure of pivotal studies to meet primary efficacy endpoints may lead to pausing, changing, or discontinuing development of other product candidates based on the ABC Platform.
• Clinical trials may encounter substantial delays or may not be completed on expected timelines, if at all, due to various factors including patient enrollment difficulties, regulatory disagreements, or adverse events.
• Product candidates may cause undesirable side effects or have other properties that could halt clinical development, prevent regulatory approval, or limit commercial potential (e.g., unexpected cataracts in GLEAM/GLIMMER studies).
• Significant competition exists in the retinal disease treatment landscape from major pharmaceutical and biotechnology companies with established products (e.g., Vabysmo, Eylea HD) and greater resources.
• The manufacturing of product candidates is highly complex, requires substantial lead time, and relies on third parties, carrying risks of material shortages, production difficulties, and failure to meet regulatory standards.
• If the company is unable to obtain and maintain patent protection for its product candidates or ABC Platform, competitors could develop and commercialize similar products.
• The company is highly dependent on key personnel, and failure to attract and retain qualified individuals could hinder business strategy implementation.
• Disruptions to information technology systems or data, including cyberattacks, could lead to adverse consequences such as regulatory investigations, fines, business interruptions, and reputational harm.
• Unfavorable U.S. and global economic conditions, including inflation, geopolitical conflicts, and bank failures, could adversely affect the business, financial condition, or results of operations.
• The ability to use net operating loss carryforwards and other tax attributes may be limited due to ownership changes or changes in tax laws.
• Changes in tax laws or regulations, such as the One Big Beautiful Bill Act (OBBBA) and the Inflation Reduction Act (IRA), could adversely affect business operations and financial performance.

Future Outlook

Kodiak Sciences intends to file a Biologics License Application (BLA) for tarcocimab in diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration in 2026, aiming to include data from the ongoing Phase 3 DAYBREAK study. Topline data for DAYBREAK (Zenkuda and KSI-501) are expected in 3Q 2026. Additionally, topline data for the Phase 3 PEAK and PINNACLE studies (KSI-101) are anticipated in 4Q 2026 and 2Q 2027, respectively. The company is also advancing its ABCD Platform for novel therapies in glaucoma and geographic atrophy, and progressing dual cytokine-targeting bispecific antibody programs (KSI-102, KSI-103) through pre-IND activities. Further development of its VETi digital health platform is also planned.

Management Comments

• Our goal is to prevent and treat the major causes of blindness by developing and commercializing next-generation therapeutics to address multiple unmet needs on the spectrum of retinal diseases.
• Zenkuda is being developed as a mainstay intravitreal biologic monotherapy that provides high immediacy and high durability, with the ultimate objective of providing, once approved, a flexible 1-month through 6-month label for all patients with retinal vascular disease.
• We believe that MESI represents a new market segment separate from the established anti-VEGF market, and KSI-101 has the potential to become a unifying treatment for this patient population.
• We believe our manufacturing efforts, including the commissioning and regulatory approval of Ursus, could position Kodiak for potential market share capture if tarcocimab and KSI-501 are approved.
• We believe that our current cash and cash equivalents will be sufficient to support our current and planned operations into 2027, but we will need to raise additional capital to maintain current operations and continue research and development activities.

Industry Context

StockSavvy.ai notes that the retinal disease treatment landscape is highly competitive and rapidly evolving, with a strong industry trend towards therapies offering extended durability and reduced treatment burden. Key competitors like Roche's Vabysmo and Regeneron's Eylea HD have already achieved significant market adoption by offering extended dosing intervals and differentiated mechanisms. Kodiak's focus on high immediacy and durability with its ABC platform, and targeting disease biology beyond VEGF with bispecifics like KSI-501 and KSI-101, aligns with these industry trends, aiming to carve out market share in a crowded space. The development of a dedicated commercial-scale manufacturing facility (Ursus) also indicates a strategic move to control supply and potentially capture market share upon approval.

Comparison to Industry Standards

• Zenkuda's mean ocular half-life in humans of 20 days is approximately three times longer than approved anti-VEGF therapies, suggesting superior durability compared to standard treatments like aflibercept (Eylea).
• In the BEACON study, 47% of Zenkuda-treated patients required no additional injections in the second 6 months, compared to only 37% of aflibercept patients, demonstrating superior durability and reduced treatment burden.
• Zenkuda's DAYLIGHT study demonstrated non-inferior efficacy to aflibercept at a once-monthly dosing interval, which is a competitive profile, though some newer competitors like Vabysmo offer up to every 16-week dosing in a meaningful proportion of patients.
• KSI-501 and KSI-101, as bispecific therapies targeting IL-6 and VEGF, aim to address disease biology beyond VEGF, potentially offering differentiated efficacy compared to anti-VEGF monotherapies like Eylea and Lucentis, and even Vabysmo which targets VEGF-A and Ang-2.
• The company's ABCD platform for glaucoma and geographic atrophy, aiming for quarterly dosing with dual mechanisms of action, seeks to surpass current approved therapies for GA (complement inhibitors requiring monthly or every other month injections) in both efficacy and durability.

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceedings at this time, though it may be subject to various legal proceedings and claims in the ordinary course of business.

Related Party Transactions

• On December 1, 2019, the company entered into a funding agreement with Baker Bros. Advisors, LP (BBA), which holds more than 5% of the company's stock. BBA purchased the right to receive a capped 4.5% royalty on future net sales of tarcocimab in exchange for $225 million, of which $100 million was received. The remaining $125 million was not paid per an amendment in July 2021.

Stakeholder Impact

• Shareholders face potential dilution from future equity financings and significant volatility in stock price due to the company's financial condition and clinical trial outcomes.
• Employees are impacted by the company's ability to attract, motivate, and retain highly qualified personnel in a competitive industry, with equity grants being a key incentive.
• Customers (future patients and healthcare providers) could benefit from new, potentially more durable and effective retinal disease treatments if product candidates receive regulatory approval.
• Creditors and investors face risks associated with the company's substantial net losses and the 'going concern' doubt, which may affect the availability and terms of future financing.
• Suppliers and contract manufacturers are critical to the company's operations, and their performance and ability to meet demand could impact the development and commercialization timelines.

Next Steps

• Announce topline data for the Phase 3 DAYBREAK study (Zenkuda and KSI-501) in wet AMD in 3Q 2026.
• Submit a Biologics License Application (BLA) for tarcocimab in DR, RVO, and wet AMD in 2026, potentially including DAYBREAK study results.
• Announce topline data readouts for the Phase 3 PEAK study (KSI-101) in MESI in 4Q 2026.
• Announce topline data readouts for the Phase 3 PINNACLE study (KSI-101) in MESI in 2Q 2027.
• Continue to progress dual cytokine-targeting bispecific antibody programs (KSI-102, KSI-103) through pre-IND activities.
• Advance retina duet programs in glaucoma and geographic atrophy built with the ABC platform towards IND.

Key Dates

Recommendation

While Kodiak Sciences has demonstrated promising clinical progress with Zenkuda in multiple Phase 3 studies and is advancing other pipeline candidates, the significant net losses and the explicit 'substantial doubt about our ability to continue as a going concern' present considerable financial risk. The recent equity raise provides some liquidity, but the need for further capital is clear. A 'hold' recommendation acknowledges the potential upside from successful BLA submissions and pipeline development, balanced against the severe financial challenges and the highly competitive market for retinal therapies. Investors should monitor upcoming clinical data readouts and the company's ability to secure additional financing.

Keywords

Retinal Disease, Biotechnology, Zenkuda, Tarcocimab, KSI-501, KSI-101, Anti-VEGF, IL-6 Inhibition, ABC Platform, ABCD Platform, Diabetic Retinopathy, Wet AMD, Retinal Vein Occlusion, Macular Edema Secondary to Inflammation, Clinical Trials, Phase 3, Drug Development, Biologics License Application, Ophthalmology, Going Concern, Equity Offering, Lonza, Ursus Facility, Glaucoma, Geographic Atrophy, VETi